Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

Genomic studies have linked mTORC1 pathway–activating mutations with exceptional response to treatment with allosteric inhibitors of mTORC1 called rapalogs. Rapalogs are approved for selected cancer types, including kidney and breast cancers. Here, we used sequencing data from 22 human kidney cancer...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Xu, Jianing, Pham, Can G., Albanese, Steven K., Dong, Yiyu, Oyama, Toshinao, Lee, Chung-Han, Rodrik-Outmezguine, Vanessa, Yao, Zhan, Han, Song, Chen, David, Parton, Daniel L., Chodera, John D., Rosen, Neal, Cheng, Emily H., Hsieh, James J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004947/
https://ncbi.nlm.nih.gov/pubmed/27482884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI86120
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы